OIG rejects management arrangement that carves out federal healthcare program patients

by McAfee & Taft
Contact

The Office of Inspector General of the Department of Health and Human Services recently posted an Advisory Opinion describing a proposed arrangement by a clinical laboratory. The lab desired to create an affiliated management company that would assist physician groups in the establishment of their own clinical labs. The management company would provide facility space, equipment and laboratory management and other support services to the physician groups, but only with respect to specimens from patients who are not federal healthcare program beneficiaries. By definition, the Medicare Anti-Kickback Statute, which prohibits payments to induce referrals of government health program patients, does not apply to non-federal business, such as specimens from patients with commercial insurance coverage or self-pay patients. However, the OIG concluded that the “carve-out” of federal healthcare business did not necessarily mean that the Medicare Anti-Kickback Statute was not implicated.

Advisory Opinion No. 13-03

A clinical laboratory requested the advisory opinion from the OIG. All arrangements between the affiliated management company and physician groups would be reduced to writing, to remain in effect for not less than one year, and would specify compensation rates consistent with fair market value in arms-length transactions. Because they would only perform services for commercial payers, the physician groups would send specimens from patients who are federal healthcare program beneficiaries, as well as specimens requiring confirmation testing, to another lab, which could include the requestor’s lab. The requestor certified that it would not require, pressure, or induce the physician groups to refer testing to it or any affiliate.

The OIG’s Analysis

Referencing a long-standing concern about arrangements under which parties carve out business generated by federal health programs from “otherwise questionable financial arrangements,” the OIG stated that such arrangements implicate the Medicare Anti-Kickback Statute “by disguising remuneration for Federal health care program business through the payment of amounts purportedly related to non-Federal health care program business.” The OIG indicated that that the requestor lab would offer the physician groups “remuneration in the form of the potentially lucrative opportunity to expand into the clinical laboratory business with little or no risk.” The OIG opined that such opportunity “may increase the likelihood” that the physicians would refer their federal government healthcare program business to the requesting lab, for reasons of convenience, to demonstrate commitment, to receive more favorable pricing on private pay services or simply because they couldn’t distinguish between the requesting lab and labs operated with its affiliated management group’s support.

Additionally, the OIG expressed concern that the financial incentives offered through the opportunity to invest in a clinical lab would affect a physician’s decision-making for all his or her patients, resulting in overutilization of laboratory services generally and increased costs to federal healthcare programs. For these reasons, the OIG concluded that the proposed arrangement could potentially generate prohibited remuneration under the Medicare Anti-Kickback Statute and that the OIG could potentially impose administrative sanctions on the requestor under the Medicare Anti-Kickback Statute.

Evaluating Your Risk

There are a number of business transactions in the healthcare industry that carve out federal healthcare program business with the goal of avoiding potential liability under the Medicare Anti-Kickback Statute. With more frequent drug testing of patients, physician groups are increasingly interested in establishing their own clinical labs. Arrangements like the one described in the advisory opinion have been proposed to avoid the difficulties encountered by physician groups in satisfying the Stark law’s physician supervision requirements. This advisory opinion makes it clear that the OIG will look beyond the terms of the arrangement to evaluate whether any federal healthcare program business may be generated among the parties. If so, the arrangement may pose compliance risk.


LINKS

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McAfee & Taft | Attorney Advertising

Written by:

McAfee & Taft
Contact
more
less

McAfee & Taft on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.